Rama Krishna Kancha Selected Research

Neoplasms (Cancer)

1/2023	Large-scale pathogenicity prediction analysis of cancer-associated kinase mutations reveals variability in sensitivity and specificity of computational methods.
1/2023	Applications of promiscuity of FDA-approved kinase inhibitors in drug repositioning and toxicity.
12/2022	Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants.
1/2021	Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances.
12/2019	Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.
1/2019	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
1/2017	Synthesis of novel forskolin isoxazole derivatives with potent anti-cancer activity against breast cancer cell lines.
1/2013	Analysis of conformational determinants underlying HSP90-kinase interaction.
1/2011	Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rama Krishna Kancha Research Topics

Disease

9	Neoplasms (Cancer) 01/2023 - 01/2011
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2023 - 05/2017
3	Lung Neoplasms (Lung Cancer) 10/2022 - 01/2018
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 01/2009
2	Breast Neoplasms (Breast Cancer) 01/2017 - 01/2011
1	Cardiotoxicity 04/2024
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2014
1	Leukemia 11/2008

Drug/Important Bio-Agent (IBA)

11	Phosphotransferases (Kinase)IBA 04/2024 - 01/2011
4	Imatinib Mesylate (Gleevec)FDA Link 10/2023 - 11/2008
3	ErbB Receptors (EGF Receptor)IBA 01/2019 - 01/2009
1	VemurafenibIBA 04/2024
1	Sorafenib (BAY 43-9006)FDA Link 04/2024
1	Metformin (Glucophage)FDA LinkGeneric 01/2023
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2023
1	Immune Checkpoint InhibitorsIBA 02/2022
1	Biomarkers (Surrogate Marker)IBA 12/2019
1	osimertinibIBA 01/2019
1	mobocertinibIBA 01/2019
1	HM781-36BIBA 01/2019
1	AfatinibIBA 01/2019
1	Tyrosine Kinase InhibitorsIBA 01/2019
1	IsoxazolesIBA 01/2017
1	Estrogen ReceptorsIBA 01/2017
1	ColforsinIBA 01/2017
1	Tyrosine (L-Tyrosine)FDA Link 01/2013
1	Lapatinib (GW572016)FDA Link 01/2011

Therapy/Procedure

4	Therapeutics 04/2024 - 05/2017